BlackRock Fund Advisors recently announced the acquisition of new stake in Amicus Therapeutics Inc. (NASDAQ:FOLD). The institutional investor has increased its shareholding in the Healthcare company by 4.21% to 19.15 million shares with purchase of 0.77 million shares. This fresh investment now brings its stake to 7.43% valued currently at $276.79 million. In addition, Janus Capital Management LLC raised its holdings by 0.17 million to 11.79 million shares. And Avoro Capital Advisor LLC has lifted its position by 0.46% or 50000.0 shares – to 11.0 million shares.
With over 1.14 million Amicus Therapeutics Inc. (FOLD) shares trading Tuesday and a closing price of $14.61 on the day, the dollar volume was approximately $16.63 million. The shares have shown a negative weekly performance of -0.51% and its price on 08/25/20 gained nearly 1.70%. Currently, there are 257.97M common shares owned by the public and among those 231.75M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 11 analysts who have offered their price forecasts for FOLD have a consensus price objective of $20.09. The analysts have set the share’s price value over the next 12 months at a high of $31.00 and a low of $12.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Amicus Therapeutics Inc. stock is 1.60 for the next 12 months. The average price target is 25.08% above its last price level and an upside to the estimated low will see the stock lose -21.75% over that period. But an upside of 52.87% will see the stock hit the forecast high price target while mean target price for the stock is $20.00.
Insiders at the company have transacted a total of 190 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 91 of these insider trades were purchases, accounting for 2,188,357 shares. Insider sales of the common stock occurred on 99 occasions, with total insider shares sold totaling 1,714,756 shares.
The top 3 mutual fund holders in Amicus Therapeutics Inc. are Vanguard Total Stock Market Index, Vanguard Small Cap Index Fund, and SPDR S&P Biotech ETF. Vanguard Total Stock Market Index owns 7.3 million shares of the company’s stock, all valued at over $105.54 million. The company sold 5956.0 shares recently to bring their total holdings to about 2.84% of the shares outstanding. Vanguard Small Cap Index Fund sold 51583.0 shares to see its total holdings shrink to 6.4 million shares valued at over $92.52 million and representing 2.49% of the shares outstanding. SPDR S&P Biotech ETF sold 53235.0 shares to bring its total holdings to over 5.31 million shares at a value of $76.79 million. SPDR S&P Biotech ETF now owns shares totaling to 2.06% of the shares outstanding.
Shares of Amicus Therapeutics Inc. (NASDAQ: FOLD) opened at $14.35, down -$0.02 from a prior closing price of $14.37. However, the script later closed the day at $14.61, up 1.70%. The company’s stock has a 5-day price change of -0.51% and 17.39% over the past three months. FOLD shares are trading 50.05% year to date (YTD), with the 12-month market performance up to 48.68% higher. It has a 12-month low price of $6.25 and touched a high of $16.13 over the same period. Currently, 1.14 million shares have been traded, compared to an average intraday trading volume of 2.74 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.03%, -1.87%, and 27.63% respectively.
Institutional ownership of Amicus Therapeutics Inc. (NASDAQ: FOLD) 257.97M shares outstanding. Mutual fund holders own 49.28%, while other institutional holders and individual stakeholders account for 61.06% and 25.52% respectively.
It has a market capitalization of $3.80B and a beta (3y monthly) value of 1.21. The earnings-per-share (ttm) stands at -$1.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.06% over the week and 3.84% over the month.
Analysts forecast that Amicus Therapeutics Inc. (FOLD) will achieve an EPS of -$0.22 for the current quarter, -$0.2 for the next quarter and -$0.68 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.27 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.24 a year ago. Earnings per share for the fiscal year are expected to increase by 21.10%, and 33.70% over the next financial year. EPS should grow at an annualized rate of -1.00% over the next five years, compared to -9.90% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 11 brokerage firm advisors rate Amicus Therapeutics Inc. (FOLD) as a “Strong Buy” at a consensus score of 1.60. Specifically, 9 Wall Street analysts polled rate the stock as a buy, while 1 of the 11 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the FOLD, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on June 17, 2020, with the firm’s price target at $19. Cantor Fitzgerald coverage for the Amicus Therapeutics Inc. (FOLD) stock in a research note released on February 04, 2020 offered a Overweight rating with a price target of $20. H.C. Wainwright was of a view on November 12, 2019 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on June 17, 2019, issuing a price target of $18. Cantor Fitzgerald on their part issued Overweight rating on June 05, 2019.